防风通圣散治疗原发性肝癌和结直肠癌术后肝转移介入栓塞后综合征的临床疗效观察  

Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer

作　　者：杨霖[1] 刘方伶 吴岩 杨国旺[1] 富琦[1] 樊庆胜[1] 张青[1] 王笑民[1] YANG Lin;LIU Fangling;WU Yan;YANG Guowang;FU Qi;FAN Qingsheng;ZHANG Qing;WANG Xiaomin(Beijing Hospital of Traditional Chinese Medicine(TCM),Capital Medical University,Beijing 100010,China;Luan Ping Hospital of TCM,Chengde 062850,China)

机构地区：[1]首都医科大学附属北京中医医院,北京100010 [2]滦平县中医院,河北承德068250

出　　处：《中国实验方剂学杂志》2023年第15期103-109,共7页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：河北省中医药管理局科研计划项目(2022521)。

摘　　要：目的:观察防风通圣散对原发性肝癌和结直肠癌术后肝转移介入化疗栓塞后综合征的疗效。方法:将原发性肝癌和结直肠癌术后肝转移患者接受经导管肝动脉化疗栓塞术并发生栓塞后综合征的患者72例随机分为治疗组(防风通圣散)和对照组(酒精擦浴+冰袋物理降温),每组36例;治疗组服用防风通圣散汤剂,对照组予以酒精擦浴联合冰袋物理降温,2组疗程均7 d。期间,观察2组患者发热、卡式评分、肝区疼痛、恶心、呕吐、便秘和肝功能情况。结果:与对照组比较,治疗组治疗后患者发热情况明显改善,体温明显降低(P<0.05),发热持续时间明显缩短(P<0.05),提示防风通圣散能明显改善介入化疗栓塞后综合征患者体温情况;与对照组比较,治疗组患者卡氏评分明显升高(P<0.05);与对照组比较,治疗组患者疼痛情况明显缓解,疼痛时间明显缩短(P<0.05);此外,防风通圣散治疗后患者恶心、呕吐、便秘程度明显减轻(P<0.05),恶心、呕吐、便秘持续时间明显缩短(P<0.05);同时,治疗组患者肝功能相关指标血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、γ-谷氨酰转肽酶(GGT)、总胆红素(TBIL)水平均明显降低(P<0.05),提示防风通圣散能明显改善介入化疗栓塞后综合征患者肝功能损伤情况。结论:防风通圣散对原发性肝癌和结直肠癌术后肝转移介入化疗栓塞后综合征有较好的疗效。Objective:To observe the effect of the Fangfeng Tongshengsan on post-chemoembolization syndrome with primary liver cancer or postoperative liver metastases of colorectal cancer.Method:Seventy-two patients suffered from post-chemoembolization syndrome after transcatheter hepatic arterial chemoembolization were randomly divided into 2 groups,including a Fangfeng Tongshengsan group and a control group,with 36 patients in each group.The patients in Fangfeng Tongshengsan group orally took the decoction for consecutive 7 d.The patients in the control group were physically cooled down with alcohol rub bath and ice pack for consecutive 7 d.Furthermore,the difference of fever,Karnofsky performance status(KPS),pain in the liver region,nausea vomiting,constipation,and liver function between these two groups were observed.Result:Compared with the control group,Fangfeng Tongshengsan significantly relieved fever,reduced the body temperature(P<0.05),and shortened the duration of fever(P<0.05),indicating that Fangfeng Tongshengsan remarkably improved the KPS(P<0.05).Meanwhile,Fangfeng Tongshengsan obviously alleviated nausea,vomiting,and constipation status and shortened the duration time compared with the control group(P<0.05).In addition,the parameters of liver function including alanine aminotransferase(ALT),aspartate aminotransferase(AST),γ-glutamyl transpeptidase(GGT),and total bilirubin(TBIL)were significantly decreased in the Fangfeng Tongshengsan group(P<0.05),which indicated that Fangfeng Tongshengsan alleviated liver dysfunction of patients with post-chemoembolization syndrome.Conclusion:Fangfeng Tongshengsan can be used to treat post-chemoembolization syndrome with primary liver cancer and postoperative liver metastases of colorectal cancer.

关 键 词：防风通圣散 栓塞后综合征 经导管肝动脉化疗栓塞 原发性肝癌 结直肠癌术后肝转移 

分 类 号：R22[医药卫生—中医基础理论] R242[医药卫生—中医学] R2-031R287